Isotechnika Pharma Inc. (ISA.TO) announced that it has received notification that ILJIN Life Science Co., Ltd. has submitted a request for arbitration relating to Isotechnika's termination of their Development, Distribution and License Agreement or "DDL".
"We are confident that our termination of the original DDL is valid, and are prepared for arbitration proceedings. We plan on continuing to engage companies, including ILJIN, who have expressed interest in working with us to advance our lead program," said Robert Foster, Isotechnika's CEO.
by RTT Staff Writer
For comments and feedback: email@example.com